Kura Oncology (NASDAQ:KURA) and IntelGenx Technologies (OTCMKTS:IGXT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Kura Oncology and IntelGenx Technologies, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kura Oncology 0 0 7 0 3.00
IntelGenx Technologies 0 0 3 0 3.00

Kura Oncology presently has a consensus price target of $27.29, indicating a potential upside of 207.62%. IntelGenx Technologies has a consensus price target of $1.37, indicating a potential upside of 425.64%. Given IntelGenx Technologies’ higher possible upside, analysts clearly believe IntelGenx Technologies is more favorable than Kura Oncology.

Earnings & Valuation

This table compares Kura Oncology and IntelGenx Technologies’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kura Oncology N/A N/A -$63.14 million ($1.51) -5.87
IntelGenx Technologies $1.82 million 15.75 -$10.11 million ($0.14) -1.86

IntelGenx Technologies has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than IntelGenx Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Kura Oncology has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, IntelGenx Technologies has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.


This table compares Kura Oncology and IntelGenx Technologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kura Oncology N/A -29.76% -27.10%
IntelGenx Technologies -792.90% -162.47% -62.47%

Insider & Institutional Ownership

85.6% of Kura Oncology shares are held by institutional investors. 11.0% of Kura Oncology shares are held by insiders. Comparatively, 13.9% of IntelGenx Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kura Oncology Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California.

IntelGenx Technologies Company Profile

IntelGenx Technologies Corp., a drug delivery company, focuses on the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. It offers RIZAPORT, an oral thin film formulation of rizatriptan benzoate for the treatment of acute migraines. The company's products under development comprise INT0001/2004, an anti-hypertension drug; INT0004/2006, an antidepressant; INT0007/2006 for the treatment of erectile dysfunction; INT0008/2008 for migraine; INT0010/2006 for the treatment of neuropathic pain and nausea in cancer patients; INT0027/2011 to treat opioid dependence; INT0036/2013 for schizophrenia; and INT0043/2015 to treat Alzheimer's disease. It is also developing INT0037/2013, INT0039/2013, INT0040/2014, INT0045/2018, INT0046/2018. The company has co-development and commercialization agreements with RedHill Biopharma Ltd., Par Pharmaceutical Companies, Inc., and Endo Ventures Ltd.; licensing, development, and supply agreement with Tilray, Inc., Gensco Pharma, and Chemo Group; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.